Media & Press
-
Phebra welcomes PBS listing of Naproxen
Naproxen suspension is approved for reinbursement through the Pharmaceutical Benefits Scheme (PBS)
November 2012
-
TGA approval of Phebra’s Naproxen oral suspension
The Australian pharmaceutical company Phebra, announced today that the Therapeutic Goods Administration (TGA) has granted Phebra marketing approval for Naproxen oral suspension, an alternative to the previously available Naprosyn® oral suspension.
October 2012
-
Phebra achieves milestone during new plant construction
Works continue to progress on the construction of Phebra pharmaceuticals’ new Sydney manufacturing plant.
May 2012
-
Phebra signs distribution agreement for Digifab
Phebra signs distribution agreement for Digifab
January 2012
-
Phebra Pharmaceuticals Welcomes New Federal Ministers
Phebra Pharmaceuticals Welcomes New Federal Ministers
December 2011
-
Tadim receives marketing approval in Australia
Tadim receives marketing approval in Australia
February 2011
-
Phebra Injects $16 Million into new manufacturing plant
Phebra Injects $16 Million into new manufacturing plant
February 2011
-
New $16 Million Manufacturing Plant
New $16 Million Manufacturing Plant
January 2011